Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-25 @ 1:34 AM
Ignite Modification Date: 2025-12-25 @ 1:34 AM
NCT ID: NCT01624194
Eligibility Criteria: Inclusion Criteria: * Medically healthy outpatients between 6 and 12 years of age (cut off 12 years and 11 months) * Intelligence Quotient \> 40 * Diagnosis of autism spectrum disorder based on the Autism Diagnostic Interview - Revised, Autism Diagnostic Observation Schedule, and DSM-IV criteria * Clinical Global Impression severity rating of 4 or higher * Care provider who can reliably bring subject to clinic visits, provide trustworthy ratings, and interacts with the subject on a regular basis * Stable medications for at least 4 weeks * No planned changes in psychosocial interventions during the trial * Willingness to provide blood samples. Exclusion Criteria: * Diagnostics and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) diagnosis of schizophrenia, schizoaffective disorder, or psychotic disorder * Regular nasal obstruction or nosebleeds * Active medical problems: unstable seizures, significant physical illness (e.g., serious liver, renal, or cardiac pathology) * Sensitivity to preservatives (in particular E 216, E 218, and chlorobutanol hemihydrate) * A genetic abnormality (e.g., Fragile X Syndrome) * Significant hearing or vision impairments * Habitually drinks large volumes of water * Pregnancy, breastfeeding, or child birth within the last 6 months * Sexually active females not using a reliable method of contraception.
Healthy Volunteers: False
Sex: ALL
Minimum Age: 6 Years
Maximum Age: 12 Years
Study: NCT01624194
Study Brief:
Protocol Section: NCT01624194